Publications by Alessia De Masi

Systems genetics of metabolic health in the BXD mouse genetic reference population

Johan Auwerx, Xiaoxu Li, Jia Liu, Maroun Bou Sleiman, Wen Gao, Amélia Lalou, Alessia De Masi, Jean-David Horacio Morel

Susceptibility to metabolic syndrome (MetS) is dependent on genetics, environment, and gene-by-environment interactions, rendering the study of underlying mechanisms challenging. The majority of experiments in model organisms do not incorporate genetic var ...

2024

Cyclo His-Pro Attenuates Muscle Degeneration in Murine Myopathy Models

Johan Auwerx, Xiaoxu Li, Alessia De Masi, Tanes Imamura de Lima, Keno Strotjohann

Among the inherited myopathies, a group of muscular disorders characterized by structural and metabolic impairments in skeletal muscle, Duchenne muscular dystrophy (DMD) stands out for its devastating progression. DMD pathogenesis is driven by the progress ...

Wiley2024

Safe and Orally Bioavailable Inhibitor of Serine Palmitoyltransferase Improves Age-Related Sarcopenia

Johan Auwerx, Tanes Imamura de Lima, Sandra Rodriguez Lopez, Alessia De Masi, Jean-David Horacio Morel

The accumulation of ceramides and related metabolites has emerged as a pivotal mechanism contributing to the onset of age-related diseases. However, small molecule inhibitors targeting the ceramide de novo synthesis pathway for clinical use are currently u ...

2024

Cyclo(His-Pro): A further step in the management of steatohepatitis

Johan Auwerx, Xiaoxu Li, Qi Wang, Adrienne Joëlle Laurence Mottis, Alexis Rapin, Alessia De Masi

Background & Aims: Non-alcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH) have become the world's most common liver diseases, placing a growing strain on healthcare systems worldwide. Nonetheless, no effective pharmacological treatment has be ...

ELSEVIER2023

Characterization of Cyclo His-Pro for the prevention and treatment of liver disease and muscular dystrophy

Alessia De Masi

The natural compound Cyclo Histidine-Proline (CHP) was initially discovered in the brain, but thereafter evaluated in the context of diabetes because of its hypoglycemic action. The pharmacokinetics and the toxicological profile of CHP showed it can be dos ...

EPFL2023

Cyclo (His-Pro) Prevents Diet-Induced Fatty Liver Disease

Johan Auwerx, Xiaoxu Li, Qi Wang, Adrienne Joëlle Laurence Mottis, Alexis Rapin, Alessia De Masi

WILEY2022